Show simple item record

dc.contributor.authorMacinnis, RJ
dc.contributor.authorAntoniou, AC
dc.contributor.authorEeles, RA
dc.contributor.authorSeveri, G
dc.contributor.authorAl Olama, AA
dc.contributor.authorMcGuffog, L
dc.contributor.authorKote-Jarai, Z
dc.contributor.authorGuy, M
dc.contributor.authorO'Brien, LT
dc.contributor.authorHall, AL
dc.contributor.authorWilkinson, RA
dc.contributor.authorSawyer, E
dc.contributor.authorArdern-Jones, AT
dc.contributor.authorDearnaley, DP
dc.contributor.authorHorwich, A
dc.contributor.authorKhoo, VS
dc.contributor.authorParker, CC
dc.contributor.authorHuddart, RA
dc.contributor.authorVan As, N
dc.contributor.authorMcCredie, MR
dc.contributor.authorEnglish, DR
dc.contributor.authorGiles, GG
dc.contributor.authorHopper, JL
dc.contributor.authorEaston, DF
dc.date.accessioned2018-06-13T11:02:41Z
dc.date.issued2011-09
dc.identifier.citationGenetic epidemiology, 2011, 35 (6), pp. 549 - 556
dc.identifier.issn0741-0395
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1858
dc.identifier.eissn1098-2272
dc.identifier.doi10.1002/gepi.20605
dc.description.abstractGenome wide association studies have identified several single nucleotide polymorphisms (SNPs) that are independently associated with small increments in risk of prostate cancer, opening up the possibility for using such variants in risk prediction. Using segregation analysis of population-based samples of 4,390 families of prostate cancer patients from the UK and Australia, and assuming all familial aggregation has genetic causes, we previously found that the best model for the genetic susceptibility to prostate cancer was a mixed model of inheritance that included both a recessive major gene component and a polygenic component (P) that represents the effect of a large number of genetic variants each of small effect, where . Based on published studies of 26 SNPs that are currently known to be associated with prostate cancer, we have extended our model to incorporate these SNPs by decomposing the polygenic component into two parts: a polygenic component due to the known susceptibility SNPs, , and the residual polygenic component due to the postulated but as yet unknown genetic variants, . The resulting algorithm can be used for predicting the probability of developing prostate cancer in the future based on both SNP profiles and explicit family history information. This approach can be applied to other diseases for which population-based family data and established risk variants exist.
dc.formatPrint-Electronic
dc.format.extent549 - 556
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectHumans
dc.subjectProstatic Neoplasms
dc.subjectModels, Statistical
dc.subjectProbability
dc.subjectRisk
dc.subjectPolymorphism, Single Nucleotide
dc.subjectAlgorithms
dc.subjectModels, Genetic
dc.subjectAdult
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectAustralia
dc.subjectMale
dc.subjectGenetic Variation
dc.subjectGenome-Wide Association Study
dc.subjectMolecular Epidemiology
dc.subjectUnited Kingdom
dc.titleA risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact.
dc.typeJournal Article
dcterms.dateAccepted2011-05-31
rioxxterms.versionofrecord10.1002/gepi.20605
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2011-09
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfGenetic epidemiology
pubs.issue6
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Dearnaley)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy/Stereotactic and Precision Body Radiotherapy (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Dearnaley)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy/Stereotactic and Precision Body Radiotherapy (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume35
pubs.embargo.termsNot known
icr.researchteamClinical Academic Radiotherapy (Dearnaley)en_US
icr.researchteamClinical Academic Radiotherapy (Huddart)en_US
icr.researchteamOncogeneticsen_US
icr.researchteamStereotactic and Precision Body Radiotherapyen_US
dc.contributor.icrauthorHorwich, Alanen
dc.contributor.icrauthorKhoo, Vincenten
dc.contributor.icrauthorDearnaley, Daviden
dc.contributor.icrauthorEeles, Rosalinden
dc.contributor.icrauthorHuddart, Roberten
dc.contributor.icrauthorKote-Jarai, Zsofiaen
dc.contributor.icrauthorParker, Chrisen
dc.contributor.icrauthorvan As, Nicken


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record